Ascorbic acid inhibits antitumor activity of bortezomib in vivo

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632 · see citing works

Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma

Richardson, P. G. G., Sonneveld, P., Schuster, M. W., Irwin, D. H., Stadtmauer, E. A., Facon, T. T. F., Harousseau, J., Ben‐Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,488 · see citing works

Vitamin C as an Antioxidant: Evaluation of Its Role in Disease Prevention

Padayatty, S. J., Katz, A., Wang, Y., Eck, P., Kwon, O., Lee, J.-H., Chen, S., Corpe, C., Dutta, A., Dutta, S. K., et al. (2003) · Journal of the American College of Nutrition · doi:10.1080/07315724.2003.10719272 · Cited by 1,949 · see citing works

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899 · see citing works

Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance

Levine, M., Conry-Cantilena, C., Wang, Y., Welch, R. W., Washko, P. W., Dhariwal, K. R., Park, J. B., Lazarev, A., Graumlich, J. F., King, J., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.8.3704 · Cited by 1,325 · see citing works

Vitamin C pharmacokinetics: Implications for oral and intravenous use

Padayatty, S. J., Sun, H., Wang, Y., Riordan, H. D., Hewitt, S. M., Katz, A., Wesley, R. A., & Levine, M. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-7-200404060-00010 · Cited by 992 · see citing works

Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy

Hideshima, T., Chauhan, D., Shima, Y., Raje, N. S., Davies, F. E., Tai, Y., Treon, S. P., Lin, B. K., Schlossman, R. L., Richardson, P. G. G., et al. (2000) · Blood · doi:10.1182/blood.v96.9.2943 · Cited by 874 · see citing works

Chemotherapy-Associated Oxidative Stress: Impact on Chemotherapeutic Effectiveness

Conklin, K. A. (2004) · Integrative Cancer Therapies · doi:10.1177/1534735404270335 · Cited by 752 · see citing works

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C. C., Joseph, M. G., Libermann, T. A., Treon, S. P., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202445099 · Cited by 744 · see citing works

Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression

Orlowski, R. Z., Nagler, A., Sonneveld, P., Bladé, J., Hájek, R., Spencer, A. G., Miguel, J. F. S., Robak, T., Dmoszyńska, A., Horvath, N., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5460 · Cited by 644 · see citing works

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

Hideshima, T., Bradner, J. E., Wong, J. Y. Y., Chauhan, D., Richardson, P. G. G., Schreiber, S. L., & Anderson, K. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503221102 · Cited by 598 · see citing works

Should Supplemental Antioxidant Administration Be Avoided During Chemotherapy and Radiation Therapy?

Lawenda, B. D., Kelly, K. M., Ladas, E. J., Sagar, S. M., Vickers, A. J., & Blumberg, J. B. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn148 · Cited by 474 · see citing works

The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status

Pérez‐Galán, P., Roué, G., Villamor, N., Montserrat, E., Campo, E., & Colomer, D. (2005) · Blood · doi:10.1182/blood-2005-05-2091 · Cited by 460 · see citing works

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

Hideshima, T., Catley, L. P., Yasui, H., Ishitsuka, K., Raje, N. S., Mitsiades, C. S., Podar, K., Munshi, N. C., Chauhan, D., Richardson, P. G. G., et al. (2006) · Blood · doi:10.1182/blood-2005-08-3434 · Cited by 423 · see citing works

Phase I clinical trial of i.v. ascorbic acid in advanced malignancy

Hoffer, L. J., Levine, M., Assouline, S., Melnychuk, D., Padayatty, S. J., Rosadiuk, K., Rousseau, C., Robitaille, L., & Miller, W. H. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn377 · Cited by 375 · see citing works

Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

Catley, L. P., Weisberg, E., Kiziltepe, T., Tai, Y., Hideshima, T., Neri, P., Tassone, P., Atadja, P. W., Chauhan, D., Munshi, N. C., et al. (2006) · Blood · doi:10.1182/blood-2006-04-016055 · Cited by 335 · see citing works

Antimyeloma activity of heat shock protein-90 inhibition

Mitsiades, C. S. (2005) · Blood · doi:10.1182/blood-2005-03-1158 · Cited by 317 · see citing works

Proteasome Inhibition Measurements: Clinical Application

Lightcap, E. S., McCormack, T. A., Pien, C. S., Chau, V., Adams, J., & Elliott, P. J. (2000) · Clinical Chemistry · doi:10.1093/clinchem/46.5.673 · Cited by 297 · see citing works

Resistance to Paclitaxel Is Proportional to Cellular Total Antioxidant Capacity

Ramanathan, B., Jan, K.-Y., Chen, C., Hour, T., Yu, H., & Pu, Y. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1162 · Cited by 287 · see citing works

Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro

Kurbacher, C. M., Wagner, U. A. G., Kolster, B., Andreotti, P. E., Krebs, D., & Bruckner, H. W. (1996) · Cancer Letters · doi:10.1016/0304-3835(96)04212-7 · Cited by 235 · see citing works

Vitamin C Antagonizes the Cytotoxic Effects of Antineoplastic Drugs

Heaney, M. L., Gardner, J. R., Karasavvas, N., Golde, D. W., Scheinberg, D. A., Smith, E. A., & O’Connor, O. A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1490 · Cited by 229 · see citing works

Clinical Pharmacokinetics of Antioxidants and Their Impact on Systemic Oxidative Stress

Schwedhelm, E., Maas, R., Troost, R., & ger, R. H. B. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342050-00003 · Cited by 171 · see citing works

Combination of Proteasome and HDAC Inhibitors for Uterine Cervical Cancer Treatment

Lin, Z., Bazzaro, M., Wang, M., Chan, K. C. G., Peng, S., & Roden, R. B. S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1813 · Cited by 109 · see citing works

Vitamin C Inactivates the Proteasome Inhibitor PS-341 in Human Cancer Cells

Zou, W., Yue, P., Lin, N., He, M., Zhou, Z., Lonial, S., Khuri, F. R., Wang, B., & Sun, S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0503 · Cited by 107 · see citing works

Ascorbic acid in the prevention and treatment of cancer.

Ka, H. (1998) · PubMed · Cited by 99 · see citing works

Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib

Liu, F., Agrawal, S. G., Movasaghi, Z., Wyatt, P. B., Rehman, I. U., Gribben, J. G., Newland, A. C., & Jia, L. (2008) · Blood · doi:10.1182/blood-2008-04-150227 · Cited by 92 · see citing works

Chemotherapy Alonevs.Chemotherapy Plus High Dose Multiple Antioxidants in Patients with Advanced Non Small Cell Lung Cancer

Pathak, A., Bhutani, M., Guleria, R., Bal, S., Mohan, A., Mohanti, B. K., Sharma, A., Pathak, R., Bhardwaj, N. K., Prasad, K. N., et al. (2005) · Journal of the American College of Nutrition · doi:10.1080/07315724.2005.10719438 · Cited by 90 · see citing works

Redox homeostasis modulates the sensitivity of myeloma cells to bortezomib

Nerini‐Molteni, S., Ferrarini, M., Cozza, S., Caligaris‐Cappio, F., & Sitia, R. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07066.x · Cited by 72 · see citing works

Dexamethasone induces sodium-dependant vitamin C transporter in a mouse osteoblastic cell line MC3T3-E1

Fujita, I., Hirano, J., Itoh, N., Nakanishi, T., & Tanaka, K. (2001) · British Journal Of Nutrition · doi:10.1079/bjn2001406 · Cited by 70 · see citing works

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

Sonneveld, P., Hájek, R., Nagler, A., et al. (2008) · Cancer · doi:10.1002/cncr.23326 · Cited by 69 · see citing works

Vitamin C protects HL60 and U266 cells from arsenic toxicity

Karasavvas, N., Cárcamo, J. M., Stratis, G., & Golde, D. W. (2005) · Blood · doi:10.1182/blood-2003-03-0772 · Cited by 61 · see citing works

Vitamin C inhibits p53-induced replicative senescence through suppression of ROS production and p38 MAPK activity

Lee, S. K. (1998) · International Journal of Molecular Medicine · doi:10.3892/ijmm_00000068 · Cited by 60 · see citing works

Antioxidants block proteasome inhibitor function in endometrial carcinoma cells

Llobet‐Navàs, D., Eritja, N., Encinas, M., et al. (2008) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3282f24031 · Cited by 59 · see citing works

Proton pump inhibitors reduce the bioavailability of dietary vitamin C

Henry, E., Carswell, A., Wirz, A. A., Fyfe, V., & McColl, K. E. L. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02568.x · Cited by 55 · see citing works

Effect of Dietary Ascorbic Acid Intake on Tissue Vitamin C in Mice

Tsao, C. S., Leung, P. Y., & Young, M. (1987) · Journal of Nutrition · doi:10.1093/jn/117.2.291 · Cited by 52 · see citing works

Chemical Blockage of the Proteasome Inhibitory Function of Bortezomib

Fernández, Y., Miller, T. P., Denoyelle, C., Esteban, J. A., Tang, W., Bengston, A. L., & Soengas, M. S. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m511607200 · Cited by 46 · see citing works

Chemosensitizing effect of vitamin C in combination with 5-fluorouracil in vitro.

Nagy, B., Mucsi, I., Molnár, J., Varga, A., & Thurzó, L. (2003) · PubMed · Cited by 21 · see citing works

Vitamin C-Sources, Physiological Role, Kinetics, Deficiency, Use, Toxicity, and Determination

Doseděl, M., Jirkovský, E., Macáková, K., Krčmová, L., Javorská, L., Pourová, J., Mercolini, L., Remião, F., Nováková, L., Mladěnka, P., et al. (2021) · Nutrients · doi:10.3390/nu13020615 · Cited by 553 · see citing works

Vitamin C: A concentration-function approach yields pharmacology and therapeutic discoveries

Levine, M., Padayatty, S. J., & Espey, M. G. (2011) · Advances in Nutrition · doi:10.3945/an.110.000109 · Cited by 357 · see citing works

Potential Mechanisms of Action for Vitamin C in Cancer: Reviewing the Evidence

Vissers, M. C. M., & Das, A. B. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00809 · Cited by 188 · see citing works

Intravenous Vitamin C and Cancer: A Systematic Review

Fritz, H., Flower, G., Weeks, L., Cooley, K., Callachan, M., McGowan, J., Skidmore, B., Kirchner, L., & Seely, D. (2014) · Integrative Cancer Therapies · doi:10.1177/1534735414534463 · Cited by 124 · see citing works

The synergy of Vitamin C with decitabine activates TET2 in leukemic cells and significantly improves overall survival in elderly patients with acute myeloid leukemia

Zhao, H., Zhu, H., Huang, J., Zhu, Y., Hong, M., Zhu, H., Zhang, J., Li, S., Yang, L., Lian, Y., et al. (2018) · Leukemia Research · doi:10.1016/j.leukres.2017.12.009 · Cited by 112 · see citing works

Multiple Myeloma Tumor Cells are Selectively Killed by Pharmacologically-dosed Ascorbic Acid

Xia, J., Xu, H., Zhang, X., Allamargot, C., Coleman, K. L., Nessler, R., Frech, I., Tricot, G., & Zhan, F. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.02.011 · Cited by 63 · see citing works

Effect of Bortezomib on serum cystatin-C in multiple myeloma

Xiao, R. (2011) · Practical Journal of Clinical Medicine

Bortezomib:a proteasome inhibitor in the treatment of multiple myeloma

陈文明 (2008) · 白血病·淋巴瘤 · doi:10.3760/cma.j.issn.1009-9921.2008.05.003

Mechanism of resistance to proteasome inhibitor bortezomib in multiple myeloma

Li, S., Qiu, L., & Jin, F. (2016) · doi:10.3760/cma.j.issn.1009-9921.2016.04.015

Mechanisms of proteasome inhibitor bortezomib on the therapy of multiple myeloma

Zhao, N., & Ya, N. J.-J. (2011) · 白血病·淋巴瘤 · doi:10.3760/cma.j.issn.1009-9921.2011.11.020

Proteasome Inhibitors in Treatment of Multiple Myeloma

Bešše, L., Matějíková, J., Sedlaříková, L., et al. (2013) · Klinicka onkologie · doi:10.14735/amko201311 · Cited by 3 · see citing works